Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.

Fiche publication

Date publication

décembre 2025

Journal

JTO clinical and research reports

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier , Pr WESTEEL Virginie , Pr MASCAUX Céline

Tous les auteurs :
Gounant V, Greillier L, Mascaux C, Pinquie F, Carmier D, Moreau L, Roch B, Debieuvre D, Dhalluin X, Giroux-Leprieur E, Berton E, Rabeau A, Raimbourg J, Dixmier A, Naltet C, Khalil A, Ezzeddine L, El Hajjam M, Langlais A, Morin F, Westeel V, Zalcman G, Duruisseaux M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41473840

Résumé

Eastern Cooperative Oncology Group performance status 2 to 3 is associated with poor survival and chemotherapy-related adverse events (AEs). The impact of poor PS on the safety and efficacy of immune checkpoint inhibitors has not been elucidated. This study aimed to assess first-line durvalumab in patients with PS 2 to 3 with advanced NSCLC and high programmed cell death-ligand 1 (PD-L1) expression.